The novel oral anticoagulants

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 2, 2013, Pages 117-126

  Rojas Hernandez, Cristhiamm ^a   Garcia, Davida ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

anticoagulants; apixaban; dabigatran; oral anticoagulants; rivaroxaban

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; ATECEGATRAN METOXIL; BETRIXABAN; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; DAREXABAN; EDOXABAN; ENOXAPARIN; ERIBAXABAN; FONDAPARINUX; LETAXABAN; LOW MOLECULAR WEIGHT HEPARIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; RIVAROXABAN; TICLOPIDINE; TTP 889; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COST CONTROL; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE REPLACEMENT; HEMATOLOGIST; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LACTATION; ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBIN TIME; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 84874193968     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1333536     Document Type: Article

References (54)

1. Pinto D. J., Orwat M. J., Koch S., et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6, 7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem: 2007; 50 22 5339 5356 (Pubitemid 350057846)
2. Wong P. C., Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost: 2010; 104 2 302 310
3. Raghavan N., Frost C. E., Yu Z., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos: 2009; 37 1 74 81
4. ® (INN - apixaban) Summary of Product Characteristics. http://ec.europa.eu/health/documents/ community-register/2011/20110518102349/anx-102349-en.pdf
5. Wang L., He K., Maxwell B., et al. Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos: 2011; 39 2 256 264
6. Kubitza D., Becka M., Voith B., Zuehlsdorf M., Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther: 2005; 78 4 412 421 (Pubitemid 41393676)
7. ® (INN - rivaroxaban) Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000944/WC500057108.pdf. Accessed: February 1, 2013
8. Lang D., Freudenberger C., Weinz C. In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos: 2009; 37 5 1046 1055
9. Gnoth M. J., Buetehorn U., Muenster U., Schwarz T., Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther: 2011; 338 1 372 380
10. Stangier J., Rathgen K., Stähle H., Gansser D., Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol: 2007; 64 3 292 303 (Pubitemid 47283865)
11. Blech S., Ebner T., Ludwig-Schwellinger E., Stangier J., Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos: 2008; 36 2 386 399 (Pubitemid 351185753)
12. ® (INN - dabigatran etexilate) Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000829/WC500041059.pdf. Accessed: February 1, 2013
13. Härtter S., Koenen-Bergmann M., Sharma A., et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol: 2012; 74 3 490 500
14. Boerhinger-Ingelheim. Dabigatran Advisory Committee Briefing Document. Available at: http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ ucm226009.pdf. Accessed: February 1, 2013
15. Lassen M. R., Raskob G. E., Gallus A., Pineo G., Chen D., Portman R. J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med: 2009; 361 6 594 604
16. Lassen M. R., Raskob G. E., Gallus A., Pineo G., Chen D., Hornick P. ADVANCE-2 investigators Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet: 2010; 375 9717 807 815
17. Lassen M. R., Gallus A., Raskob G. E., Pineo G., Chen D., Ramirez L. M. ADVANCE-3 Investigators Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med: 2010; 363 26 2487 2498
18. Goldhaber S. Z., Leizorovicz A., Kakkar A. K., et al. ADOPT Trial Investigators Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med: 2011; 365 23 2167 2177
19. Buller H., Deitchman D., Prins M., Segers A. Botticelli Investigators, Writing Committee Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost: 2008; 6 8 1313 1318 (Pubitemid 352016310)
20. Alexander J. H., Becker R. C., Bhatt D. L., et al. APPRAISE Steering Committee and Investigators Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation: 2009; 119 22 2877 2885
21. Alexander J. H., Lopes R. D., James S., et al. APPRAISE-2 Investigators Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med: 2011; 365 8 699 708
22. Granger C. B., Alexander J. H., McMurray J. J., et al. ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2011; 365 11 981 992
23. Eikelboom J. W., O'Donnell M., Yusuf S., et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J: 2010; 159 3 348, e1
24. Eriksson B. I., Borris L. C., Friedman R. J., et al. RECORD1 Study Group Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med: 2008; 358 26 2765 2775 (Pubitemid 351930851)
25. Kakkar A. K., Brenner B., Dahl O. E., et al. RECORD2 Investigators Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet: 2008; 372 9632 31 39
26. Lassen M. R., Ageno W., Borris L. C., et al. RECORD3 Investigators Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med: 2008; 358 26 2776 2786 (Pubitemid 351930852)
27. Turpie A. G., Lassen M. R., Davidson B. L., et al. RECORD4 Investigators Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet: 2009; 373 9676 1673 1680
28. Turpie A. G., Lassen M. R., Eriksson B. I., et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost: 2011; 105 3 444 453
29. Cohen A. T., Spiro T. E., Büller H. R., et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis: 2011; 31 4 407 416
30. Cohen A. T., Buller H. R., Mebazaa A., et al. Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. The Annual Scientific Session of the American College of Cardiology. New Orleans, LA, 2011
31. Bauersachs R., Berkowitz S. D., Brenner B., et al. EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med: 2010; 363 26 2499 2510
32. Büller H. R., Prins M. H., Lensin A. W., et al. EINSTEIN-PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med: 2012; 366 14 1287 1297
33. Mega J. L., Braunwald E., Wiviott S. D., et al. ATLAS ACS 2-TIMI 51 Investigators Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med: 2012; 366 1 9 19
34. Patel M. R., Mahaffey K. W., Garg J., et al. ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med: 2011; 365 10 883 891
35. Eriksson B. I., Dahl O. E., Rosencher N., et al. RE-NOVATE Study Group Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet: 2007; 370 9591 949 956 (Pubitemid 47393577)
36. Eriksson B. I., Dahl O. E., Rosencher N., et al. RE-MODEL Study Group Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost: 2007; 5 11 2178 2185 (Pubitemid 47617868)
37. Ginsberg J. S., Davidson B. L., Comp P. C., et al. RE-MOBILIZE Writing Committee Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty: 2009; 24 1 1 9
38. Schulman S., Kearon C., Kakkar A. K., et al. RE-COVER Study Group Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med: 2009; 361 24 2342 2352
39. Schulman S., Baanstra D., Eriksson H., et al. Dabigatran versus Placebo for Extended Maintenance Therapy of Venous Thromboembolism. ISTH, Kyoto, Japan: 2011
40. Schulman S., Kakkar A. K., Schellong S. M., et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). The American Society of Hematology 2011 Annual Meeting. San Diego, CA, 2011
41. Schulman S., Eriksson H., Goldhaber S. Z., et al. Dabigatran or Warfarin for Extended Maintenance Therapy of Venous Thromboembolism. ISTH, Kyoto, Japan: 2011
42. Oldgren J., Budaj A., Granger C. B., et al. RE-DEEM Investigators Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J: 2011; 32 22 2781 2789
43. Connolly S. J., Ezekowitz M. D., Yusuf S., et al. RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151
44. Eikelboom J. W., Wallentin L., Connolly S. J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation: 2011; 123 21 2363 2372
45. Beasley B. N., Unger E. F., Temple R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med: 2011; 364 19 1788 1790
46. Adam S. S., McDuffie J. R., Ortel T. L., Williams J. W. Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med: 2012
47. Samama M. M., Martinoli J. L., LeFlem L., et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost: 2010; 103 4 815 825
48. Lindahl T. L., Baghaei F., Blixter I. F., et al. Expert group on coagulation of the external quality assurance in laboratory medicine in Sweden Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost: 2011; 105 2 371 378
49. Avecilla S. T., Ferrell C., Chandler W. L., Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol: 2012; 137 4 572 574
50. Stangier J., Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis: 2012; 23 2 138 143
51. Kaatz S., Kouides P. A., Garcia D. A., et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol: 2012; 87 01 S141 S145
52. Ganetsky M., Babu K. M., Salhanick S. D., Brown R. S., Boyer E. W. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol: 2011; 7 4 281 287
53. Al-Horani R. A., Ponnusamy P., Mehta A. Y., Gailani D., Desai U. R. Sulfated Pentagalloylglucoside Is a Potent, Allosteric, and Selective Inhibitor of Factor XIa. J Med Chem: 2013; (e-pub ahead of print)
54. Ahrens I., Peter K., Lip G. Y., Bode C. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation. Discov Med: 2012; 13 73 445 450